Biography
Dr. Arturo Loaiza-Bonilla, MD, MSEd, FACP is a physician–scientist and oncology executive operating at the intersection of clinical medicine, artificial intelligence, and large-scale clinical research infrastructure.
Clinical interests / subspecialty
Biomarker-driven cancers; immunotherapy; complex trial-based care; clinical trial access/matching infrastructure; neurosymbolic & multi-agent AI platforms
Education & training
Medical School: University of Miami Miller School of Medicine
Residency: St. Luke's-Roosevelt Hospital Center, Columbia University, Internal Medicine
Fellowship: Post-Doctorate Fellow, Hematology and Oncology (University of Miami Miller School of Medicine)
Other training: Master of Medical Education (MSEd), Medical Education (University of Pennsylvania)
Board certifications / licenses
- ABIM - Medical Oncology
- ABIM - Internal Medicine
Professional memberships
ASCO, AACR, ACP (Fellow)
Languages
English (native); French (professional working proficiency); Japanese (elementary proficiency); Spanish (native or bilingual proficiency)
Research areas
AI in clinical trials; neurosymbolic / multi-agent AI architectures; digital health; real-world data activation; precision oncology systems
Clinical research experience
Phase I–III clinical trial leadership and portfolios across oncology networks
Leadership & recognition
- 40 under 40 in Cancer; Philadelphia Business Journal “40 Under 40”; Castle Connolly / Philadelphia Magazine Top Doctors (since 2018)
Publications & media
- 80+ peer-reviewed publications in NEJM AI, JCO, Lancet Oncology, ESMO and JAMA Oncology
- PubMed
Arturo Loaiza-Bonilla reviews Massive Bio content as part of our Medical Review Board, ensuring medical accuracy and clinical currency across our cancer resources.
Content reviewed by Arturo Loaiza-Bonilla
What Is Blood Dyscrasias?
JANUARY 2024
Ce qu’il faut savoir sur le lymphome du manteau?
NOVEMBER 2023
Unlocking New Horizons: Exploring Clinical Trials for Metastatic NSCLC
OCTOBER 2023
Essais cliniques et traitements expérimentaux pour la Leucémie Lymphoblastique Aiguë de l’Enfance
OCTOBER 2023
Déverrouiller de nouveaux horizons : Exploration des essais cliniques pour le cancer du poumon non à petites cellules métastatique (CNPC-M)
OCTOBER 2023
Révolutionner le traitement de la myélofibrose : Comment les essais cliniques détiennent la clé d’un avenir meilleur
SEPTEMBER 2023
Le pouvoir de la recherche : Célébrons la Journée mondiale de la recherche sur le cancer et son impact sur le traitement du cancer
SEPTEMBER 2023
Clinical Trials Demystified by Massive Bio’s Chief Medical Officer
MARCH 2023
The Power of Supportive Care: Enhancing Life with Multiple Myeloma
MARCH 2023
Treatment Options for Myelofibrosis
MARCH 2023
Illuminating the Path: Advancements and Future Outlook in Multiple Myeloma Research
FEBRUARY 2023
What Is the Relationship Between Stress and Cancer?
FEBRUARY 2023
First Signs of Colon Cancer
JUNE 2022
What is ALK? An Ultimate Guide
APRIL 2022
Living and Managing Tips When You Have Myelofibrosis
MARCH 2022
What are the Differences Between Small Cell and Non-Small Cell Lung Cancer?
FEBRUARY 2022
Hormone Therapy for Breast Cancer
JANUARY 2022
KRAS Genes in Lung Cancer
APRIL 2021
FGFR2 Mutation
MARCH 2021
Clinical Trial Matching Tool Proven Effective
OCTOBER 2020
Relapsed Non-Hodgkin Lymphoma Clinical Trials
JULY 2020
Machine Learning in Healthcare
JULY 2020
Bile Duct Cancer and FGFR Clinical Trials
MAY 2020
First Things Know About Cancer Treatment
NOVEMBER 2017